The ICR responds to the FDA approval of talazoparib for women with BRCA-mutant advanced breast cancer 18 Oct 2018 The ICR strongly welcomes the news that talazoparib (trade name Talzenna) has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer. Find out more Show/Hide
The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018 The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer. Find out more Show/Hide
ICR awarded major prize for pioneering discoveries in precision medicines for cancer 01 Dec 2017 The Institute of Cancer Research, London, has been recognised with a highly prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery. Find out more Show/Hide